Brief: Mirati Therapeutics Announces Adagrasib (Krazati™) Receives Breakthrough Therapy Designation From FDA For Patients With Advanced, Kras-Mutated Colorectal Cancer
21/12/2022 22:03
Dec 21 (Reuters) - Mirati Therapeutics Inc MRTX.O :
* MIRATI ANNOUNCES ADAGRASIB (KRAZATI™) RECEIVES
BREAKTHROUGH
THERAPY DESIGNATION FROM FDA FOR PATIENTS WITH ADVANCED,
KRAS-MUTATED COLORECTAL CANCER AND NEJM PUBLISHES PHASE 1B/2
DATA FROM ADAGRASIB WITH OR WITHOUT CETUXIMAB IN COLORECTAL
CANCER
* MIRATI THERAPEUTICS INC - SAFETY PROFILE OF ADAGRASIB WAS
CONSISTENT WITH PREVIOUSLY REPORTED SAFETY FINDINGS
* MIRATI THERAPEUTICS INC - SAFETY OF COMBINATION OF
ADAGRASIB AND
CETUXIMAB DID NOT RESULT IN SYNERGISTIC ADVERSE EVENTS
* MIRATI THERAPEUTICS INC - PHASE 3 TRIAL EVALUATING
ADAGRASIB IN
COMBINATION WITH CETUXIMAB IS CURRENTLY ONGOING
Source text for Eikon: ID:nPnbv0h84a
Further company coverage: MRTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mirati Therapeutics
See all newsBrief: European Commission Approves KRAZATI As A Targeted Treatment For Non-Small Cell Lung Cancer
US FDA turns down Amgen lung cancer drug Lumakras for full approval (updated)
US FDA turns down Amgen lung cancer drug Lumakras for full approval
Brief: Mirati Stockholders Voted 'For' Proposal To Adopt Deal Between Co, Bristol-Myers Squibb
Mirati's lung cancer drug gets EU's regulatory backing (updated)